Financhill
Buy
55

MDGL Quote, Financials, Valuation and Earnings

Last price:
$298.27
Seasonality move :
2.04%
Day range:
$295.43 - $311.21
52-week range:
$200.63 - $377.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.61x
P/B ratio:
9.38x
Volume:
340.9K
Avg. volume:
317.2K
1-year change:
10.48%
Market cap:
$6.7B
Revenue:
$180.1M
EPS (TTM):
-$18.05

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MDGL
Madrigal Pharmaceuticals
$158.9M -$3.65 985.75% -48.55% $423.14
ALNY
Alnylam Pharmaceuticals
$633.5M -$0.05 -3.52% -58.59% $325.06
ALT
Altimmune
-- -$0.30 -100% -14.11% $20.63
BBIO
BridgeBio Pharma
$97M -$0.39 4530.37% -18.53% $60.00
CYTK
Cytokinetics
$1.9M -$1.35 706.05% -8.01% $72.55
VKTX
Viking Therapeutics
-- -$0.44 -- -120.34% $90.26
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MDGL
Madrigal Pharmaceuticals
$300.15 $423.14 $6.7B -- $0.00 0% 20.61x
ALNY
Alnylam Pharmaceuticals
$329.77 $325.06 $43B -- $0.00 0% 18.05x
ALT
Altimmune
$4.89 $20.63 $396.2M -- $0.00 0% 17,634.17x
BBIO
BridgeBio Pharma
$42.83 $60.00 $8.1B -- $0.00 0% 63.51x
CYTK
Cytokinetics
$34.36 $72.55 $4.1B -- $0.00 0% 207.19x
VKTX
Viking Therapeutics
$27.72 $90.26 $3.1B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MDGL
Madrigal Pharmaceuticals
14.24% 0.317 1.61% 5.41x
ALNY
Alnylam Pharmaceuticals
89.88% 0.837 2.91% 2.84x
ALT
Altimmune
-- 1.530 -- 15.54x
BBIO
BridgeBio Pharma
925.32% 1.065 28.12% 4.31x
CYTK
Cytokinetics
168.01% 0.167 13.74% 5.89x
VKTX
Viking Therapeutics
-- -0.142 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MDGL
Madrigal Pharmaceuticals
$132.7M -$79.3M -43.17% -49.57% -50.96% -$88.9M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
ALT
Altimmune
-- -$21.8M -62.28% -62.28% -405100% -$16.8M
BBIO
BridgeBio Pharma
$114M -$103.8M -145.93% -- -109.29% -$200.8M
CYTK
Cytokinetics
-$98.3M -$155.6M -121.06% -- -8766.94% -$137.3M
VKTX
Viking Therapeutics
-- -$55.5M -- -- -- -$31.2M

Madrigal Pharmaceuticals vs. Competitors

  • Which has Higher Returns MDGL or ALNY?

    Alnylam Pharmaceuticals has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -9.67%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About MDGL or ALNY?

    Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 40.98%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $325.06 which suggests that it could fall by -1.43%. Given that Madrigal Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Madrigal Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    ALNY
    Alnylam Pharmaceuticals
    13 7 1
  • Is MDGL or ALNY More Risky?

    Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

  • Which is a Better Dividend Stock MDGL or ALNY?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or ALNY?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.61x versus 18.05x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.61x -- $137.3M -$73.2M
    ALNY
    Alnylam Pharmaceuticals
    18.05x -- $594.2M -$57.5M
  • Which has Higher Returns MDGL or ALT?

    Altimmune has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -391500%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Altimmune's return on equity of -62.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    ALT
    Altimmune
    -- -$0.26 $142.2M
  • What do Analysts Say About MDGL or ALT?

    Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 40.98%. On the other hand Altimmune has an analysts' consensus of $20.63 which suggests that it could grow by 387.59%. Given that Altimmune has higher upside potential than Madrigal Pharmaceuticals, analysts believe Altimmune is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    ALT
    Altimmune
    5 1 0
  • Is MDGL or ALT More Risky?

    Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Altimmune has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.709%.

  • Which is a Better Dividend Stock MDGL or ALT?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or ALT?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Altimmune quarterly revenues of $5K. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Altimmune's net income of -$19.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.61x versus 17,634.17x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.61x -- $137.3M -$73.2M
    ALT
    Altimmune
    17,634.17x -- $5K -$19.6M
  • Which has Higher Returns MDGL or BBIO?

    BridgeBio Pharma has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -143.55%. Madrigal Pharmaceuticals's return on equity of -49.57% beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    BBIO
    BridgeBio Pharma
    97.74% -$0.88 $209.5M
  • What do Analysts Say About MDGL or BBIO?

    Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 40.98%. On the other hand BridgeBio Pharma has an analysts' consensus of $60.00 which suggests that it could grow by 40.09%. Given that Madrigal Pharmaceuticals has higher upside potential than BridgeBio Pharma, analysts believe Madrigal Pharmaceuticals is more attractive than BridgeBio Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    BBIO
    BridgeBio Pharma
    11 3 0
  • Is MDGL or BBIO More Risky?

    Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.412%.

  • Which is a Better Dividend Stock MDGL or BBIO?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or BBIO?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.61x versus 63.51x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.61x -- $137.3M -$73.2M
    BBIO
    BridgeBio Pharma
    63.51x -- $116.6M -$167.4M
  • Which has Higher Returns MDGL or CYTK?

    Cytokinetics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -10220.14%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Cytokinetics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    CYTK
    Cytokinetics
    -6223.05% -$1.36 $391.7M
  • What do Analysts Say About MDGL or CYTK?

    Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 40.98%. On the other hand Cytokinetics has an analysts' consensus of $72.55 which suggests that it could grow by 111.15%. Given that Cytokinetics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Cytokinetics is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    CYTK
    Cytokinetics
    9 3 0
  • Is MDGL or CYTK More Risky?

    Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.592, suggesting its less volatile than the S&P 500 by 40.763%.

  • Which is a Better Dividend Stock MDGL or CYTK?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or CYTK?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Cytokinetics quarterly revenues of $1.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than Cytokinetics's net income of -$161.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.61x versus 207.19x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.61x -- $137.3M -$73.2M
    CYTK
    Cytokinetics
    207.19x -- $1.6M -$161.4M
  • Which has Higher Returns MDGL or VKTX?

    Viking Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -49.57% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
    VKTX
    Viking Therapeutics
    -- -$0.41 --
  • What do Analysts Say About MDGL or VKTX?

    Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 40.98%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 225.63%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
    VKTX
    Viking Therapeutics
    10 2 0
  • Is MDGL or VKTX More Risky?

    Madrigal Pharmaceuticals has a beta of -1.047, which suggesting that the stock is 204.702% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

  • Which is a Better Dividend Stock MDGL or VKTX?

    Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MDGL or VKTX?

    Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 20.61x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MDGL
    Madrigal Pharmaceuticals
    20.61x -- $137.3M -$73.2M
    VKTX
    Viking Therapeutics
    -- -- -- -$45.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock